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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Drugs interacting with the hERG potassium
channel are associated with a prolongation of the
QT interval, which can lead to life-threatening
arrhythmias such as torsades de pointes.
• Early prokinetic agents, such as cisapride, display
poor selectivity for their target receptor, 5-HT4,
also interacting with hERG channels and, as a
consequence, have a poor safety and benefit/risk
profile.
• Prucalopride, a novel and selective 5-HT4 agonist
with enterokinetic activity, is indicated for the
treatment of chronic constipation in adults in
whom laxatives fail to provide adequate relief.
WHAT THIS STUDY ADDS
• This study describes the results of a novel
thorough QT study design involving a parallel
group with nested crossover for positive control.
• The mean QTc interval was not prolonged in
patients receiving therapeutic (2 mg) or
supra-therapeutic (10 mg) doses of prucalopride,
as assessed using QTcSS.
• New generation prokinetic agents with improved
selectivity for 5-HT4 receptors, such as
prucalopride, should help improve the
benefit/risk profile of these agents and,
ultimately, their clinical usefulness.
AIMS
To assess steady-state effects of therapeutic and supra-therapeutic doses of
prucalopride on the QT interval using a novel design involving a parallel
placebo group with nested crossover for positive control.
METHODS
A double-blind, double-dummy, placebo- and active-controlled study was
conducted in 120 healthy male and female volunteers (NCT00903747).
Volunteers were randomized to receive prucalopride 2–10 mg once daily
(therapeutic and supratherapeutic doses, respectively) (group 1), placebo
with 400 mg moxifloxacin on day 1 (group 2a), or placebo with
moxifloxacin on day 15 (group 2b). Twelve-lead 24 h Holter ECGs recorded
at various time-points were evaluated blind and centrally.
RESULTS
Estimated mean difference in study specific corrected QT interval (QTcSS)
time-matched change from baseline between prucalopride (2 and 10 mg)
and placebo was <5 ms at all time points (maximum mean difference:
3.83 ms at 3.5 h post dose on day 5 with 2 mg [90% Cl -0.33, 6.38 ms]).
Upper limits of the two-sided 90% CI for QTcSS were all <10 ms. There were
no outlying QTcSS values >450 ms and no subjects had an increase >60 ms
following prucalopride. Moxifloxacin produced the expected significant
changes in QTcSS (>5 ms, maximum of +12.7 ms at 5 h post dose) at all
time-points except 1 h post dose. Prucalopride resulted in small increases in
heart rate (maximum of 5.8 beats min–1), which were similar for 2 and
10 mg. Prucalopride was well tolerated after first day of treatment.
CONCLUSION
Prucalopride at both therapeutic and supra therapeutic doses has no
clinically significant effects on cardiac repolarisation in healthy volunteers.
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Introduction
Prucalopride (Resolor®) is a novel enterokinetic agent. It is
the first of a new generation of selective, high-affinity
5-HT4 receptor agonists [1–3]. This drug, which has been
developed for the treatment of chronic constipation in
adults in whom laxatives fail to provide adequate relief,
stimulates gastrointestinal (GI) motility through its effects
on 5-HT4 receptors [1,3].Clinical data, including those from
three identical pivotal phase III studies,have demonstrated
that 2 mg prucalopride once daily is effective in increasing
stool frequency, reducing constipation-related symptoms
and improving quality of life [4–6].
Concerns about possible cardiovascular effects of
enterokinetic agents arose a few years ago, prompting
market withdrawal and restrictions for the use of cisapride
and tegaserod, in 2003 and 2006, respectively. It is now com-
monly accepted that there should be a 30-fold separation (or
safety margin) between maximum unbound drug concen-
trations in humans and the human ether a-go-go related
gene (hERG) potassium channel halfmaximal inhibitory con-
centration (IC50), to reduce the potential risk of cardiac pro-
arrhythmia such as torsade de pointes [7]. In contrast with
cisapride,whichhas amargin of less than 10-fold between its
affinity for 5-HT4 and hERG channels (binding studies), pru-
caloprideat its therapeuticdose ismore than200 timesmore
selective for 5-HT4 than for the hERG channels [2]. With
regard to functional testsmeasuringhERGcurrents,cisapride
has no discernable safety margin between its hERG IC50 and
its therapeutic concentration [7]. Conversely, prucalopride
blocks hERGchannelswith an IC50 value rangingbetween4.1
and 22 mM [8, 9], which is equivalent to a safety margin of at
least 200 times the therapeutic plasma concentration and,as
such, significantly exceeds the recommended threshold of
30-fold IC50 [7].
Furthermore, there is no evidence of ECG irregularities
or cardiac arrhythmias in healthy volunteer or clinical
studies [1, 3–5, 10–15], including studies in elderly patients
with previous cardiovascular history [16].
The main objective of this thorough QT study was to
evaluate the cardiac safety of prucalopride in accordance
with the ICH E14 guideline,by assessing its effect on theQT
interval when administered to healthy volunteers at thera-
peutic (2 mg) and supratherapeutic (10 mg) doses [17, 18].
The supratherapeutic dose used in this study was assessed
and found to be safe in a previous phase I cardiac safety
study, and is likely to be the maximum dose tolerated in
the majority of healthy volunteers (unpublished data).This
dose, however, has to be titrated in order to be tolerated,
which led to a novel thorough QT study design involving a
parallel group with nested crossover for positive control,
thereby reducing the number of subjects by half. In accor-
dance with the E14 guideline, a positive control,moxifloxa-
cin (400 mg), was included to establish the sensitivity of
the study to detect relevant small changes in the QT inter-
val [17].
Methods
Subjects
The study (NCT00903747) enrolled 120 healthy male and
female non-smoking volunteers aged 18–50 years, with a
bodymass index (BMI) of 18–30 kg m-2 and bodyweight of
50 kg. Eligible volunteers were in good health (deter-
mined by physical examination, 12-lead ECG and clinical
laboratory evaluations), had a normal ECG and no clinically
significant medical history.Concomitant medications were
not allowed,except for paracetamol up to 3 ¥ 500 mg day-1
and no more than 3 g week-1. All volunteers gave written
informed consent prior to any study related procedures.
The study was approved by an independent Ethics
Committee (Welwyn Clinical Pharmacology Ethics Com-
mittee, Hatfield, Hertfordshire, UK) and was conducted in
accordance with the principles of the Declaration of Hels-
inki (1996 version), Good Clinical Practice guidelines and
other applicable regulatory requirements.
Study design
This was a phase I, double-blind, randomized,placebo- and
positive-controlled parallel group/crossover study.A single
oral dose of 400 mg moxifloxacin was included as a posi-
tive control, by means of a crossover design nested within
the placebo arm of the parallel group design.
Volunteers were randomized to one of three treatment
groups: group 1 (prucalopride, 2 mg tablets manufactured
by Sanico NV, Turnhout, Belgium), group 2a or group 2b
(placebo/moxifloxacin [Avelox®, Bayer HealthCare AG,
Leverkusen, Germany]). Subjects in group 1 received a
once daily dose of 2 mg prucalopride on days 1 to 5, after
which dosing escalated by 2 mg day-1 to a maximum dose
of 10 mg on day 9, and continued once daily dosing with
10 mg prucalopride on days 10 to 13. Subjects also
received a single dose of placebo (in packaging identical to
that of moxifloxacin) on days 1 and 15, to ensure blinding
of moxifloxacin intake in groups 2a and 2b. Subjects in
groups 2a and 2b received a single dose of 400 mg moxi-
floxacin on day 1 or day 15, respectively, and placebo
tablets matching the group 1 prucalopride dosing on days
1 to 13, as well as a single dose of placebo (in packaging
identical to that of moxifloxacin) on day 15 or day 1, for
groups 2a and 2b, respectively. No dose was administered
on day 14. Volunteers remained in the study centre from
day -2 until day 16.
Randomization was performed using a randomly per-
muted 2:1:1 block allocation scheme for groups 1, 2a and
2b, stratified by gender.
Assessments
To ensure blinding, all assessments were performed in all
groups at all time-points.
Twelve-lead ECGs were recorded using the Mortara
Instrument (Milwaukee, WI, USA) H12+ (1000 Hz) continu-
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ous 12-lead ECG digital recorder and saved onto a flash
card.ECGs were read centrally by an independent assessor,
blinded to the type of treatment and the date and time of
recording. Standard 12-lead ECGs were extracted in tripli-
cate for each time point from the 12-lead Holter data
recordings on day -1 (baseline, time-matched to ECGs on
assessment days),days 5 and 13 (for prucalopride effect) at
pre dose and 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 23.5 h post
dose,on day 13 at 36 and 48 h post dose and on days 1 and
15 (for assay sensitivity) at pre-dose, and 1, 2, 3, 4, 5 and 6 h
post dose.
ECG intervals were measured digitally on a computer
screen by trained cardiovascular technicians who were
blinded to subject and treatment group using a propri-
etary validated electronic calliper system (WebHeartTM).For
each 12-lead ECG, three consecutive magnified PQRST
complexes and their preceding RR intervals were manually
measured. Measurements were performed from V3 (pre-
ferred) or lead II (back up),with the same lead used for each
subject wherever possible. Cardiologists, each of whom
read all of the ECGs for a given subject, verified the interval
durations and performed the morphological analysis and
diagnostic interpretation.
To assess plasma concentrations of prucalopride,blood
samples (4 ml) were taken on days 5 and 13 at the same
time point as the ECGs.A validated liquid chromatography
with tandem mass spectrometry method was used with a
lowest and highest limit of quantification of 0.2 and
100 ngml-1, respectively. Accuracy ranged from 98.5 to
101.3% and the coefficient of variation ranged from 0.4 to
5.6%.
Safety assessments included physical examinations,
vital signs, resting 12-lead ECGs, 24 h Holter monitoring,
safety clinical laboratory tests (biochemistry, haematology
and urinalysis) and adverse event (AE) monitoring.
Statistical methods
The primary endpoint was defined as the QTcSS time-
matched change from baseline,where QTcSS =QT/RRl, and
the exponent l was derived as the median value (within
genders) of the regression coefficient of loge(QT) on
loge(RR) using baseline data. The regression coefficients
were estimated separately for each volunteer, and the
median values were determined for males and females
separately. Other corrections calculated were QTcF and
QTcB using the Fridericia [19] and Bazett [20] corrections,
respectively (data not reported here).
Analysis of covariance (ANCOVA) was performed on the
time-matched change frombaseline in QTcSS,separately at
each time point (mean of triplicate ECGs), with treatment
(active and placebo) and gender as categorical variables
and (time-matched) baseline QTcSS as a linear covariate.
Groups 2a and 2b were pooled for this analysis.Absence of
effects of prucalopride on cardiac repolarization (i.e. non-
inferiority vs. placebo) was concluded if the upper limit of
the 90% two-sided Cl for the difference of prucalopride
from placebo for all time points was below the non-
inferiority margin of 10 ms. All statistical analyses were
conducted using SAS Version 9 or later.
In addition, a comparison between moxifloxacin
(400 mg) and placebo, to demonstrate assay sensitivity,
was performed in groups 2a and 2b, regarded as an AB/BA
crossover design. The ANCOVA model included treatment,
period, sequence and subject. A two-sided 90% CI was
derived for the QTcSS difference (moxifloxacin minus
placebo) at all time points.Assay sensitivity was considered
demonstrated if the lower limit of the CI for the QTcSS
difference between moxifloxacin and placebo was5 ms.
The sample size of 120 volunteers was based on a
between and within subject standard deviation (SD) for
the (baseline adjusted) gender dependent, study specific
corrected QT interval (QTcSS) of 11 ms (unpublished data).
For prucalopride, it was assumed that the true QTcSS effect
relative to placebo was 3 ms. The moxifloxacin effect was
expected to be at least 12 ms at its highest point [21].
Results
Subject disposition and demographics
A total of 352 volunteers were screened, and 120 of these
were enrolled and randomized to either prucalopride
(group 1, n = 60), moxifloxacin/placebo (Group 2a, n = 30)
or placebo/moxifloxacin (group 2b,n = 30).There were four
withdrawals from the study (all female): one from the pru-
calopride group (day 10, due to vomiting and nausea), and
three from themoxifloxacin/placebo group (one on day 11
due to personal reasons, one on day 7 due to an AE [pal-
pable lymph node] and one on day 10 due to a protocol
deviation).All other subjects completed the study.The data
from all randomized subjects were included in the analysis.
The majority of volunteers in the three treatment
groups were Caucasian (group 1: 76.7%, group 2a: 66.7%
and group 2b: 70.0%) and male (56.7% in all groups), with
a BMI (mean  SD) of 23.6  2.6, 24.6  3.0 and 23.9 
2.4 kg m-2 for group 1, 2a and 2b, respectively. Mean age
(27.7–29.9 years), height (171.8–174.4 cm) and weight
(70.5–73.0 kg) were comparable for all treatment groups.
Change in QTcSS from baseline
In order to derive the male and female study specific cor-
rection factor (l), the relationship between QT and RR was
assessed for each subject.The median values of the slopes
of the regression analysis of log (QT) and log (RR) were
0.296 for men and 0.357 for women, both of which were
close in value to the Fridericia correction factor (0.333).The
QTcF values were therefore very similar to the QTcSS values
and for that reason are not further discussed.
The mean changes in QTcSS for both 2 and 10 mg pru-
calopride were similar to placebo over the 24 h and 48 h
period, respectively. The estimated mean difference in
QTcSS time-matched change from baseline between both
Prucalopride thorough QT study in healthy volunteers
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2 mg prucalopride and placebo as well as between 10 mg
prucalopride and placebo was <5 ms at all time points
studied on day 5 and day 13, respectively. These ranged
from 0.89 ms (90% CI -3.43, 5.21 ms) at 12 h post dose to
3.83 ms (90% CI -0.28, 7.94 ms) at 3.5 h post dose for 2 mg
prucalopride. For 10 mg prucalopride, they ranged from
-0.75 ms (90% CI -4.11, 2.60 ms) at 12 h post dose to
3.03 ms (90% CI -0.33,6.38 ms) at 2.5 h post dose.All lower
limits were below zero and each corresponding upper limit
of the two-sided 90% CI was below the 10 ms non-
inferiority margin (Figure 1).
Moxifloxacin vs. placebo (assay sensitivity)
At all individual time points, except at 1 h post dose, the
lower limit of the 90% CI of the difference in QTcSS time-
matched change from baseline between moxifloxacin and
placebo was >5 ms.Mean QTcSS changes from baseline for
moxifloxacin increased up to +12.7 ms (5 h post dose),
while the mean QTcSS change from baseline for placebo
fluctuated post dose between -0.7 ms and +0.8 ms. This
confirms that the assay was sufficiently sensitive to detect
a QTc prolongation tendency associated with a single dose
of moxifloxacin.
The mean QTcSS during treatment with moxifloxacin
was overall somewhat higher in group 2a (day 1) com-
pared with group 2b (day 15). A difference between the
groups was already observed pretreatment. Differences
were considered not clinically relevant.
Heart rate, PR and QRS
Differences in time-matched changes in HR from baseline
between 2 mg prucalopride (day 5) and placebo were
positive at all time points studied and were of the same
order at the supratherapeutic dose of 10 mg (day 13).
Changes were mostly statistically significant, of the order
of 2–5 beats min-1, but did not exceed 6 beats min-1 fol-
lowing either 2 mg prucalopride (4.71 beats min-1, 90% CI
2.18, 7.24 beats min-1, 12 h post dose), or 10 mg prucalo-
pride (5.80 beats min-1, 90% CI 3.54, 8.06 beats min-1, 3.5 h
post dose).
Consistent with the change in HR, non-clinically rel-
evant decreases in mean PR interval were observed: 2 mg
range -3.8 ms (5 h) to -10.7 (2 h) ms, and 10 mg range
-2.2 ms (36 h) to -10.1 (2 h) ms. Despite an increase in
dose, the mean differences remained of the same order.
Mean changes from baseline in QRS for 2 mg prucalo-
pride ranged from -0.3 ms (24 h) to 1.8 ms (0 h), and for
10 mg prucalopride from -0.4 ms (24 h) to 1.4 ms (5 h and
36 h).
Outlier analysis
There were no outlying QTcSS values >450 ms at any time
point following either 2 mg or 10 mg prucalopride. The
number of occurrences of QTcSS increases of 30–60 ms
frombaselinewas low in the prucalopride treated subjects:
seven for 2 mg prucalopride (five for placebo) (day 5), 12
for 10 mg prucalopride (eight for placebo) (day 13), while
those for moxifloxacin were 21 (five for placebo). There
were only isolated occurrences of an increase >60 ms and
the number did not exceed two in any group.
ECG morphology analysis
No ventricular arrhythmias were observed and no ECG
abnormalities were considered to be of clinical signifi-
cance or recorded as an AE. There were no significant dif-
ferences between prucalopride and placebo in ECG
morphology changes or arrhythmia.
Pharmacokinetics of prucalopride
Following a dose of 2 mg daily, prucalopride was rapidly
absorbed, reaching amean Cmax of 7.37 ng ml-1 at amedian
time of 2 h post dose on day 5 (at steady state). At the
10 mg dose, Cmax reached a mean of 42.7 ng ml-1 2 h post
dose on day 13, a 5.8-fold increase in exposure for a 5-fold
increase in dose. AUC over the dosing interval increased
from 108 ngml-1 h following daily dosing with 2 mg to
590 ngml-1 h following 10 mg daily dosing, a 5.5-fold
increase.
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Figure 1
MeanQTcSS differences (ms) in time-matched change from baseline between A) prucalopride (2 mg) and placebo,and B) prucalopride (10 mg) and placebo,
by time point. Error bars represent 90% CIs. The solid line indicates the usual 10 ms regulatory threshold
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Safety
Overall, 105 (88%) volunteers in groups 1, 2a and 2b
reported a total of 450 treatment-emergent AEs. These
were more common on the first day of treatment with
prucalopride (2 mg).The incidence of diarrhoea, headache
and nausea was 57%, 80% and 22%, respectively, on pru-
calopride vs. 2%, 7% and 2%, respectively, with placebo.
From day 2 to 5, there were considerably fewer reports of
diarrhoea (15%), headache (10%) and nausea (7%) with
prucalopride treatment. The corresponding incidences for
placebo were 10%,7% and 0%, respectively.Most AEs were
mild or moderate and related to study medication. There
were no severe AEs. Only one serious AE (spontaneous
abortion during placebo treatment) and two AEs leading
to withdrawal (see earlier section in Results). There was no
observable dose-related trend in treatment-emergent AEs
in the prucalopride group.
There were no observable dose-related trends, clini-
cally relevant changes or notable differences in treatment
groups in any vital signs parameters, ECG safety param-
eters or laboratory safety parameters.
Discussion
This thorough QT study, which was performed in compli-
ance with the ICH E14 Guidance on Clinical Evaluation of
QT/QTc Interval Prolongation, and which met the require-
ments for assay sensitivity, confirmed that prucalopride at
both therapeutic (2 mg) [4–6] and supratherapeutic doses
(10 mg) had no detectable effect on cardiac repolarization.
A randomized, two-arm parallel-group design was chosen
because of the need to titrate the doses up to a suprath-
erapeutic level for tolerability reasons.
The design chosen for this study is novel, reducing the
number of subjects required to exclude a repolarization
effect, by combining the two active groups (therapeutic
and supratherapeutic) and by nesting the positive control
treatment within the placebo arm of the study, resulting in
effectively two study groups,active and control.This is pos-
sible because the positive control (moxifloxacin) has a rela-
tively short half-life (compared with prucalopride), and
provided that there is a sufficient period of washout
between positive control and placebo observations
(1–2 days), the comparisons with prucalopride are not
compromised.
By subdividing the placebo group, the design is
arranged such that one subgroup receives the positive
control at the beginning of the study (group 2a) and the
other receives it at the end (group 2b, 2 days after the final
supratherapeutic day for prucalopride). Thus, an AB/BA
crossover design (positive control vs.placebo) can be used,
which gives the advantage that any time or environmental
related changes in the QTc interval which take place during
the study can be isolated (and eliminated) in the positive
control analysis.
Although the design proved efficient in this study,extra
care was required with the study blinding. In particular, to
maintain blinding, dummy ECGs were collected for the
prucalopride group on days where ECG measurements
were required to assess the positive control in the placebo
groups. Although, in general, assay sensitivity can be
achieved with open label moxifloxacin [18], in a study with
a nested crossover design blinding of the active control is
required, as open-label moxifloxacin would effectively
unblind the placebo group.
The use of universal QT correction methods, such as
Bazett’s (QTcB) and Fridericia’s (QTcF), has been questioned
as these may introduce errors in estimating drug-induced
QT prolongation, secondary to changes in heart rate [22].
The use of customized QT correction methods, such as the
individual QT correction (QTcI), based on individual regres-
sion models computed from a set of QT/RR measurements
collected during drug free periods, has been promoted as
the best alternative to the universal correction methods
[23].However, based on practical and theoretical consider-
ations, a large number of drug free ECGs are required to
ensure reliable calculations of QTcl [24].
Alternatively, population specific or study specific QT
correction methods (QTcSS) have been suggested, which
utilize themean ormedian of all individual QT/RR slopes to
generate a common slope for all study participants [25].
However such an approach introduces a possible bias due
to gender differences if the allocation ofmales and females
to the groups is imbalanced. In this study, this was avoided
by the use of separate medians for males and females.
Furthermore, when QTcl is derived from a limited number
of ECG data points it shows marginally increased variance
(and hence lower power) compared with QTcSS. Given the
limited number of drug free ECGs available for the deriva-
tion of a customized QT correction, we preferred to avoid
the QTcI method in this study for the reasons discussed
above. The study specific correction yielded gender spe-
cific exponents of 0.296 and 0.357, respectively. Conse-
quently, for this study, the QTcSS results were similar to the
QTcF results.
For both therapeutic and supratherapeutic doses, the
upper limit of the two-sided 90% CI for the difference in
time-matched QTcSS change from baseline between pru-
calopride and placebo was below the non-inferiority
margin of 10 ms at all time points. In addition, no subject
(male or female) had a QTcSS increase greater than 60 ms,
resulting in QTcSS greater than 500 ms (the threshold of
clinical and regulatory concern) with either dose of pruca-
lopride.There were also no significant differences between
prucalopride and placebo in ECG morphology changes or
arrhythmias, and no clinically relevant abnormalities were
observed.
Importantly, this study confirmed the expected QTc
effect associated with the positive control moxifloxacin.
During the first 6 h after administration, the moxifloxacin
baseline and placebo adjusted QTcSS mean effect and
Prucalopride thorough QT study in healthy volunteers
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lower 90% CI limit were above the 5 ms regulatory thresh-
old at all time points, except at 1 h post dose for the lower
90% CI. For this analysis, the QTcSS values of the parallel
groups 2a and 2b were combined. It is therefore of interest
to compare the QTcSS values of groups 2a (day 1) and 2b
(day 15).The values were similar although themean values
for group 2a were somewhat lower than for group 2b.
However the differences remained well within the stan-
dard deviation. Also on non-treatment days the QTcSS
values were around 5 ms lower for group 2a, except at 1 h
where they were 1–2 ms higher. These findings reinforce
confidence in the validity of the results obtained with
prucalopride.
Both doses of prucalopride were associated with a
small and, in most cases, statistically significant increase in
HR, which is not considered to be clinically relevant. A
small, transient increase in HRwith prucalopride treatment
has also been observed in animals. An extended series of
safety pharmacology studies with special emphasis on car-
diovascular parameters showed no relevant changes in
haemodynamic or ECG-derived parameters (QTc), with the
exception of a modest increase in heart rate and blood
pressure in conscious dogs after bolus intravenous admin-
istration, which was not observed either in anaesthetized
dogs or after oral administration in dogs reaching similar
plasma concentrations [26].
Consistent with the change in HR, non-clinically rel-
evant decreases in mean PR interval were observed,which
were similar for 2 and 10 mg prucalopride. QRS interval
showed the same pattern.
The pharmacokinetics of prucalopride are linear and
the supratherapeutic dose of 10 mg represents a 5-fold
increase in exposure of that of the therapeutic dose of
2 mg. Metabolism is not a major route of elimination of
prucalopride and a large fraction of the drug is excreted
unchanged. Prucalopride has a low potential for drug–
drug interactions. It is not expected to alter the pharmaco-
kinetics of drugs metabolized by the cytochrome P450
system, nor are these drugs expected to affect the dispo-
sition of prucalopride. Although prucalopride may be a
weak substrate for P-glycoprotein (P-gp), it is not an inhibi-
tor of P-gp at clinically relevant concentrations. No effect
on the plasma concentrations of prucalopride was
observed with erythromycin, paroxetine, cimetidine and
probenecid [26]. Ketoconazole, at a high dose of 200 mg
twice daily, increased the area under the curve of prucalo-
pride by approximately 40% [26] which is likely attribut-
able to inhibition of P-gp mediated renal transport.
Prucalopride may also be secreted via other renal trans-
porters and inhibition of all transporters involved in the
active secretion of prucalopride may theoretically increase
its exposure by up to 75%. Assuming this worst case sce-
nario, the supra-therapeutic dose of 10 mg still yields an
almost 3-fold increase of this exposure. Therefore the
choice of 10 mg once daily as the supratherapeutic dose
for this study appears appropriate.
Treatment with prucalopride at doses up to 10 mg
once daily was safe and well tolerated from day 2 onwards.
The high incidence of gastrointestinal-related treatment-
emergent AEs in the prucalopride group is due to the phar-
macodynamic action of the drug and ismore often seen on
days 1–2 of treatment, consistent with findings previously
reported [4–6].
In conclusion, this thorough QT study, conducted in
accordance with the ICH E14 Guidance on Clinical Evalua-
tion of QT/QTc Interval Prolongation, found no evidence of
QT prolongation or pro-arrhythmic potential for prucalo-
pride in healthy volunteers, at doses up to five times the
recommended therapeutic dose. At both therapeutic
(2 mg) and supratherapeutic (10 mg) doses, the upper CI
for the time-matched changes from baseline QTcSS values
were below the 10 ms regulatory threshold at all time
points, confirming the absence of any clinically relevant
effect of prucalopride on cardiac repolarization.The results
with the positive control, moxifloxacin, demonstrated that
this study was sufficiently sensitive to detect a QT prolon-
gation of themagnitude of regulatory and clinical concern.
At doses of 2 mg and 10 mg prucalopride,a small and clini-
cally irrelevant increase in HRwas observed,but therewere
no significant differences between prucalopride and
placebo in ECG morphological changes or arrhythmias.
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